1. Pink Sheet
  2. >>Geography
  3. >>Asia
  4. >>South Korea

Korea's New Fast Track Scheme A GIFT For High-Need Drugs

Nefecon, Pegcetacoplan Selected

 
• By Jung Won Shin

South Korea designates two more global innovative products for support under a new fast track system, in a move set to speed up patient access to novel therapies.

fast track
Strategic Support On Horizon In Korea For Rapid Launch, Export Of Innovative Drugs • Source: Shutterstock

South Korea's Ministry of Food and Drug Safety (MFDS) has designated two orphan drugs - Calliditas Therapeutics AB’s budesonide and Apellis Pharmaceuticals, Inc.’s pegcetacoplan - as the second and third products to be accepted into the newly established Global Innovative Products on Fast Track (GIFT) scheme, meaning they will receive support from early-stage clinical trials to enable more rapid commercialization.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from South Korea

More from Asia

Pipeline To Product – What Is Driving Cell And Gene Therapy Progress In India?

 
• By Vibha Ravi

US-based Colossal Labs has claimed to bring back the dire wolf from extinction. While the science is not as dramatic in India yet, cell and gene therapies are making progress as treatments for cancer and other diseases. Pink Sheet takes a look at what is driving CGT success and growth.

Japan Identifies Drugs ‘In Urgent Need’ Of Development

 
• By Lisa Takagi

Artesunate for malaria, TB drug pretomanid and omadacycline for pneumonia and skin infections are among the drugs identified by Japanese regulatory authorities in urgent need of domestic development.

US Tariff Impact On Korea Dissected As Country Gears For Presidential Election

 
• By Jung Won Shin

Analysts expect a limited impact on South Korean pharma from US tariffs, even if imposed at a later date. Meanwhile, the early June domestic presidential election is set to determine the direction of policies in the sector.